Survival Without Disability to Age 5 Years After Neonatal Caffeine Therapy for Apnea of Prematurity

Caffeine for Apnea of Prematurity (CAP), Mark van der Hoeven

Research output: Contribution to journalArticleAcademicpeer-review

211 Citations (Web of Science)

Abstract

Very preterm infants are prone to apnea and have an increased risk of death or disability. Caffeine therapy for apnea of prematurity reduces the rates of cerebral palsy and cognitive delay at 18 months of age.To determine whether neonatal caffeine therapy has lasting benefits or newly apparent risks at early school age.Five-year follow-up from 2005 to 2011 in 31 of 35 academic hospitals in Canada, Australia, Europe, and Israel, where 1932 of 2006 participants (96.3%) had been enrolled in the randomized, placebo-controlled Caffeine for Apnea of Prematurity trial between 1999 and 2004. A total of 1640 children (84.9%) with birth weights of 500 to 1250 g had adequate data for the main outcome at 5 years.Combined outcome of death or survival to 5 years with 1 or more of motor impairment (defined as a Gross Motor Function Classification System level of 3 to 5), cognitive impairment (defined as a Full Scale IQ
Original languageEnglish
Pages (from-to)275-282
JournalJAMA-Journal of the American Medical Association
Volume307
Issue number3
DOIs
Publication statusPublished - 18 Jan 2012

Cite this